Visual Abstract

Background: Primary membranous nephropathy (pMN) is less common in women of child-bearing age. The kidney risk factors to adverse maternal-fetal outcomes and the effects of pregnancy on pMN process need to be investigated. Methods: We retrospectively screened all the patients with biopsy-proven pMN from 2008 to 2018. Any cases of pregnancy that occurred at the time of pMN diagnosis or during follow-up were included in the study. Clinical and pathological data were collected from all patients at the time of kidney biopsy and their gestational results were recorded. Results: Of the 27 pregnancies with gestational time of 35.9 ± 4.5 weeks, 10 adverse maternal-fetal events occurred, including fetal loss (11%), preterm delivery (26%), and severe preeclampsia (15%). The kidney parameters were relatively stable with all preserved kidney function. Time-averaged urinary protein (p < 0.001) and serum albumin (p < 0.001), maximum urinary protein (p = 0.001) and minimum serum albumin (p = 0.01) before week 20, anti-phospholipase A2 receptor (PLA2R) positivity (p = 0.03), and no remission during pregnancy (p = 0.004) were risk factors to adverse maternal-fetal outcomes. Time-averaged urinary protein and serum albumin correlated with the birth weight percentile of neonates. Conclusions: Pregnancy in pMN patients showed risks to adverse maternal-fetal events. Heavy proteinuria, especially before week 20 of gestation, severe hypoalbuminemia, positive anti-PLA2R, and no remission were risk factors to worse outcomes.

1.
Francis JM, Beck LH Jr, Salant DJ. Membranous nephropathy: a journey from bench to bedside. Am J Kidney Dis. 2016 Jul;68(1):138–47.
2.
Dahan K, Gillion V, Johanet C, Debiec H, Ronco P. The Role of PLA2R Antibody in Treatment of Membranous Nephropathy. Kidney Int Rep. 2017 Nov;3(2):498–501.
3.
Debiec H, Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med. 2011 Feb;364(7):689–90.
4.
Ayalon R, Beck LH Jr. Membranous nephropathy: not just a disease for adults. Pediatr Nephrol. 2015 Jan;30(1):31–9.
5.
Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol. 2017 Jun;12(6):983–97.
6.
Barceló P, López-Lillo J, Cabero L, Del Río G. Successful pregnancy in primary glomerular disease. Kidney Int. 1986 Dec;30(6):914–9.
7.
Packham DK, North RA, Fairley KF, Whitworth JA, Kincaid-Smith P. Membranous glomerulonephritis and pregnancy. Clin Nephrol. 1987 Aug;28(2):56–64.
8.
Jungers P, Chauveau D. Pregnancy in renal disease. Kidney Int. 1997 Oct;52(4):871–85.
9.
Malik GH, Al-Harbi AS, Al-Mohaya S, Al-Wakeel J, Al-Hozaim W, Kechrid M, et al. Repeated pregnancies in patients with primary membranous glomerulonephritis. Nephron. 2002 May;91(1):21–4.
10.
Liu Y, Ma X, Lv J, Shi S, Liu L, Chen Y, et al. Risk factors for pregnancy outcomes in patients with IgA nephropathy: a matched cohort study. Am J Kidney Dis. 2014 Nov;64(5):730–6.
11.
Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009 Jul;361(1):11–21.
12.
Al-Rabadi L, Ayalon R, Bonegio RG, Ballard JE, Fujii AM, Henderson JM, et al. Pregnancy in a Patient With Primary Membranous Nephropathy and Circulating Anti-PLA2R Antibodies: A Case Report. Am J Kidney Dis. 2016 May;67(5):775–8.
13.
Irish G, Jesudason S: Case study of tacrolimus as an effective treatment for idiopathic membranous glomerulonephritis in pregnancy. Obstet Med. DOI: 10.1177/1753495X18816923.
14.
Sebestyen A, Varbiro S, Sara L, Deak G, Kerkovits L, Szabo I, et al. Successful management of pregnancy with nephrotic syndrome due to preexisting membranous glomerulonephritis: a case report. Fetal Diagn Ther. 2008;24(3):186–9.
15.
Aoshima Y, Iyoda M, Nakazawa A, Yamaguchi Y, Kuroki A, Shibata T, et al. Membranous nephropathy that first presented in pregnancy. Intern Med. 2013;52(17):1949–52.
16.
Valecha S, Maimoona A, Dhingra D, Gandhewar M. Rare case of pregnancy with nephrotic syndrome complicated with IVC and renal vein thrombosis. Int J Pharm Sci Invent. 2013;12:17–9.
17.
Ope-Adenuga S, Moretti M, Lakhi N. Management of membranous glomerulonephritis in pregnancy: a multidisciplinary challenge. Case Rep Obstet Gynecol. 2015;2015:839376.
18.
Quevedo J, Mohamed M, Ebrahimi F. Membranous Nephropathy Diagnosed During Pregnancy: American Journal of Kidney Diseases, WB Saunders Co-Elsevier Inc 1600 John F Kennedy Boulevard, STE 1800, Philadelphia, PA 19103-2899 USA, 2015. p. A69.
19.
Lu S, Liu D, Xiao J, Zhang X, Liu Z, Zhao Z. New-onset idiopathic membranous nephropathy in pregnancy. Int J Clin Exp Med. 2016;9(11):22625–31.
20.
Kaushal S, Dogra P, Malhotra K, Sharma R, Kumar A. Membranous nephropathy in pregnancy- A case report and review of literature. J Adv Med Dent Scie Res. 2017;5(4):81–3.
21.
Uchino E, Takada D, Mogami H, Matsubara T, Tsukamoto T, Yanagita M. Membranous nephropathy associated with pregnancy: an anti-phospholipase A2 receptor antibody-positive case report. CEN Case Rep. 2018 May;7(1):101–6.
22.
Who EC; WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004 Jan;363(9403):157–63.
23.
Kidney Disease Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012;2:139–274.
24.
Kong X, Ma Y, Chen J, Luo Q, Yu X, Li Y, et al.; Chinese eGFR Investigation Collaboration. Evaluation of the Chronic Kidney Disease Epidemiology Collaboration equation for estimating glomerular filtration rate in the Chinese population. Nephrol Dial Transplant. 2013 Mar;28(3):641–51.
25.
Dai L, Deng C, Li Y, Zhu J, Mu Y, Deng Y, et al. Birth weight reference percentiles for Chinese. PLoS One. 2014 Aug;9(8):e104779.
26.
Jungers P, Houillier P, Forget D, Henry-Amar M. Specific controversies concerning the natural history of renal disease in pregnancy. Am J Kidney Dis. 1991 Feb;17(2):116–22.
27.
O’Shaughnessy MM, Jobson MA, Sims K, Liberty AL, Nachman PH, Pendergraft WF. Pregnancy Outcomes in Patients with Glomerular Disease Attending a Single Academic Center in North Carolina. Am J Nephrol. 2017;45(5):442–51.
28.
De Castro I, Easterling TR, Bansal N, Jefferson JA. Nephrotic syndrome in pregnancy poses risks with both maternal and fetal complications. Kidney Int. 2017 Jun;91(6):1464–72.
29.
Jungers P, Forget D, Henry-Amar M, Albouze G, Fournier P, Vischer U, et al. Chronic kidney disease and pregnancy. Adv Nephrol Necker Hosp. 1986;15:103–41.
30.
Abe S, Amagasaki Y, Konishi K, Kato E, Sakaguchi H, Iyori S. The influence of antecedent renal disease on pregnancy. Am J Obstet Gynecol. 1985 Nov;153(5):508–14.
31.
Surian M, Imbasciati E, Cosci P, Banfi G, Barbiano di Belgiojoso G, Brancaccio D, et al. Glomerular disease and pregnancy. A study of 123 pregnancies in patients with primary and secondary glomerular diseases. Nephron. 1984;36(2):101–5.
32.
Katz AI, Davison JM, Hayslett JP, Singson E, Lindheimer MD. Pregnancy in women with kidney disease. Kidney Int. 1980 Aug;18(2):192–206.
33.
Noel LH, Zanetti M, Droz D, Barbanel C. Long-term prognosis of idiopathic membranous glomerulonephritis. Study of 116 untreated patients. Am J Med. 1979 Jan;66(1):82–90.
34.
Studd JW, Blainey JD. Pregnancy and the nephrotic syndrome. BMJ. 1969 Feb;1(5639):276–80.
35.
Forland M, Spargo BH. Clinicopathological correlations in idiopathic nephrotic syndrome with membranous nephropathy. Nephron. 1969;6(4):498–525.
36.
Koratala A, Wakefield DN, Vangapalli A, Ejaz AA. Course of membranous nephropathy during multiple gestations. BMJ Case Rep. 2016 Nov;2016:pii:bcr2016218363.
37.
Iwakura T, Fujigaki Y, Katahashi N, Sato T, Ishigaki S, Tsuji N, et al. Membranous Nephropathy with an Enhanced Granular Expression of Thrombospondin Type-1 Domain-containing 7A in a Pregnant Woman. Intern Med. 2016;55(18):2663–8.
38.
Huang YM, Zhou HR, Zhang L, Yang KK, Luo JX, Zhao HL. Spontaneous remission of membranous glomerulonephritis with successful fetal outcome: A case report and literature review. Medicine (Baltimore). 2016 Jun;95(26):e4022.
39.
Aoshima Y, Iyoda M, Nakazawa A, Yamaguchi Y, Kuroki A, Shibata T, et al. Membranous nephropathy that first presented in pregnancy. Intern Med. 2013;52:1949–52.
40.
Szucs KA, Axline SE, Rosenman MB. Maternal membranous glomerulonephritis and successful exclusive breastfeeding. Breastfeed Med. 2010 Jun;5(3):123–6.
41.
Cho FN, Liu CB. Potential role of intravenous immunoglobulin in the management of peripartum maternal thrombocytopenia due to various causes. J Chin Med Assoc. 2008 May;71(5):267–9.
42.
Gunasekara AP, Atherton J, McDonald N, Meulet J. A unique presentation of antiphospholipid antibody syndrome in pregnancy. Heart Lung Circ. 2005 Jun;14(2):87–9.
43.
Katzir Z, Rotmensch S, Boaz M, Biro A, Michlin A, Smetana S. Pregnancy in membranous glomerulonephritis—course, treatment and outcome. Clin Nephrol. 2004 Jan;61(1):59–62.
44.
Koethe JD, Gerig JS, Glickman JL, Sturgill BC, Bolton WK. Progression of membranous nephropathy to acute crescentic rapidly progressive glomerulonephritis and response to pulse methylprednisolone. Am J Nephrol. 1986;6(3):224–8.
45.
Feng XL, Guo S, Hipgrave D, Zhu J, Zhang L, Song L, et al. China’s facility-based birth strategy and neonatal mortality: a population-based epidemiological study. Lancet. 2011 Oct;378(9801):1493–500.
46.
Chen C, Zhang J, Xia H, Zhang H, Betran AP, Zhang L, et al. Epidemiology of preterm birth in China in 2015 and 2016: a nationwide survey. Lancet. 2018;392:S73.
47.
Chen Y, Li G, Ruan Y, Zou L, Wang X, Zhang W. An epidemiological survey on low birth weight infants in China and analysis of outcomes of full-term low birth weight infants. BMC Pregnancy Childbirth. 2013 Dec;13(1):242.
48.
Ye C, Ruan Y, Zou L, Li G, Li C, Chen Y, et al. The 2011 survey on hypertensive disorders of pregnancy (HDP) in China: prevalence, risk factors, complications, pregnancy and perinatal outcomes. PLoS One. 2014 Jun;9(6):e100180.
49.
Mi J, Liu F. Rate of caesarean section is alarming in China. Lancet. 2014 Apr;383(9927):1463–4.
50.
Limardo M, Imbasciati E, Ravani P, Surian M, Torres D, Gregorini G, et al.; Rene e Gravidanza Collaborative Group of the Italian Society of Nephrology. Pregnancy and progression of IgA nephropathy: results of an Italian multicenter study. Am J Kidney Dis. 2010 Sep;56(3):506–12.
51.
Sangle SR, Vounotrypidis P, Briley A, Nel L, Lutalo PM, Sanchez-Fernandez S, et al. Pregnancy outcome in patients with systemic vasculitis: a single-centre matched case-control study. Rheumatology (Oxford). 2015 Sep;54(9):1582–6.
52.
Blom K, Odutayo A, Bramham K, Hladunewich MA. Pregnancy and Glomerular Disease: A Systematic Review of the Literature with Management Guidelines. Clin J Am Soc Nephrol. 2017 Nov;12(11):1862–72.
53.
Brown RA, Kemp GJ, Walkinshaw SA, Howse M. Pregnancies complicated by preeclampsia and non-preeclampsia-related nephrotic range proteinuria. Obstet Med. 2013 Dec;6(4):159–64.
54.
Stritzke A, Thomas S, Amin H, Fusch C, Lodha A. Renal consequences of preterm birth. Mol Cell Pediatr. 2017 Dec;4(1):2–2.
55.
Saji F, Samejima Y, Kamiura S, Koyama M. Dynamics of immunoglobulins at the feto-maternal interface. Rev Reprod. 1999 May;4(2):81–9.
56.
Su X, Lv J, Liu Y, Wang J, Ma X, Shi S, et al. Pregnancy and Kidney Outcomes in Patients With IgA Nephropathy: A Cohort Study. Am J Kidney Dis. 2017 Aug;70(2):262–9.
57.
Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation. 2001 Apr;71(8):1051–5.
58.
Paziana K, Del Monaco M, Cardonick E, Moritz M, Keller M, Smith B, et al. Ciclosporin use during pregnancy. Drug Saf. 2013 May;36(5):279–94.
59.
Cravedi P, Remuzzi G, Ruggenenti P. Rituximab in primary membranous nephropathy: first-line therapy, why not? Nephron Clin Pract. 2014;128(3-4):261–9.
60.
Fiorentino M, Tondolo F, Bruno F, Infante B, Grandaliano G, Gesualdo L, et al. Treatment with rituximab in idiopathic membranous nephropathy. Clin Kidney J. 2016 Dec;9(6):788–93.
61.
Das G, Damotte V, Gelfand JM, Bevan C, Cree BA, Do L, et al. Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD. Neurol Neuroimmunol Neuroinflamm. 2018 Mar;5(3):e453.
62.
Harris C, Marin J, Beaulieu MC. Rituximab induction therapy for de novo ANCA associated vasculitis in pregnancy: a case report. BMC Nephrol. 2018 Jun;19(1):152.
63.
Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011 Feb;117(5):1499–506.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.